An unusual FDA panel on antidepressant use during pregnancy elevated skeptics of the drugs

What's new in pharma

July 25, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | An unusual FDA panel on antidepressant use during pregnancy elevated skeptics of the drugs Makary is recruiting researchers to weigh in on hormone therapy and SSRIs. The panels seem to have a bias, and the FDA's goal is unclear. By Lizzy Lawrence STAT+ | Europe moves to reject embattled Duchenne muscular dystrophy gene therapy Regulatory decisions elsewhere mean the Sarepta drug, Elevidys, is not being shipped anywhere worldwide. By Andrew Joseph Opinion: Plans to test prior authorization in traditional Medicare are deeply troubling WISeR, a Medicare demonstration program from the CMS Innovation Center, will not cut waste — but it will hurt seniors. By Donald M. Berwick and Andrea Ducas Courtesy Eli Lilly STAT+ | European regulators endorse Lilly's Alzheimer's treatment for certain patients Regulators had initially said the drug should be rejected, but issued a limited approval recommendation following an appeal. By Andrew Joseph

More around STAT

---

Correction: Yesterday's newsletter had an outdated subject line. We regret the error. Happy Friday.

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser